MediciNova, Inc.
MNOV · Nasdaq · United States
Share price · MNOV
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when MNOV's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 28 Sep 2026-18.6%
- 22 Sep 2026-12.1%
Nothing announced by MNOV that day or the session before.
- 17 Sep 2026+36.9%
Nothing announced by MNOV that day or the session before.
- 16 Sep 2026+24.8%
Nothing announced by MNOV that day or the session before.
- 15 Sep 2026+8.0%
Nothing announced by MNOV that day or the session before.
- 8 Sep 2026+7.4%
Nothing announced by MNOV that day or the session before.
- 3 Sep 2026+13.3%
- Day beforeTermination of a material agreement
- 24 Aug 2026+10.1%
Nothing announced by MNOV that day or the session before.
- 17 Jul 2026-4.9%
Nothing announced by MNOV that day or the session before.
- 1 Jul 2026+7.6%
Nothing announced by MNOV that day or the session before.
Share of unusual movement by asset
For each asset, the share of MNOV's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Tipelukastevents and moves
| 2 | shown from 8 days |
Ibudilastevents and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 3% |
| Other company news (earnings, financing, releases naming no asset) | — | 2% |
| Sessions with no dated event | — | 94% |
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2/3 | PDE4 and PDE10; macrophage migration inhibitory factor (MIF)Small molecule | AsthmaAmyotrophic Lateral Sclerosis | |
| Phase 2 | Cysteinyl leukotriene receptor 1 (CysLT1) / PDE3 / PDE4 / 5-lipoxygenaseSmall molecule | Type 2 DiabetesMASH / NASHCardiovascular Disease / Dyslipidemia Hypertriglyceridemia |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $0.1M | $1.1M | $29M | $2.8M-$2.4M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $0.5M | $0.9M | $25M | $2.3M-$1.9M operating cash flow | report ↗ |
| 2026-Q1 | $0.2M | $1.2M | $27M | $2.6M-$3.5M operating cash flow | report ↗ |
| 2025-Q3 | $0.1M | $1.5M | $33M | $3.0M-$1.7M operating cash flow | report ↗ |
| 2025-Q2 | $0.1M | $2.0M | $34M | $3.3M-$2.3M operating cash flow | report ↗ |
| 2025-Q1 | — | $1.7M | $37M | $2.9M-$3.8M operating cash flow | report ↗ |
| 2024-Q3 | — | $1.8M | $42M | $2.9M-$2.0M operating cash flow | report ↗ |
| 2024-Q2 | — | $1.5M | $44M | $2.6M-$2.8M operating cash flow | report ↗ |
| 2024-Q1 | — | $1.7M | $47M | $2.8M-$3.9M operating cash flow | report ↗ |
| 2023-Q3 | $1.0M | $0.7M | $52M | $0.7M-$1.4M operating cash flow | report ↗ |
| 2023-Q2 | — | $1.6M | $53M | $2.9M-$2.4M operating cash flow | report ↗ |
| 2023-Q1 | — | $1.4M | $55M | $2.9M-$3.2M operating cash flow | report ↗ |
| 2022-Q3 | — | $2.4M | $53M | $3.6M-$2.7M operating cash flow | report ↗ |
| 2022-Q2 | — | $2.5M | $65M | $4.0M-$2.5M operating cash flow | report ↗ |
| 2022-Q1 | — | $2.0M | $68M | $3.4M-$3.7M operating cash flow | report ↗ |
| 2021-Q3 | <$0.1M | $2.0M | $75M | $3.6M-$3.0M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0.4M | $6.7M | $31M | $3.0M-$9.8M operating cash flow | report ↗ |
For FY2025, MediciNova reported revenue of $0.41M, with no revenue recorded in the prior year. R&D spend was $6.7M, down 1.5% YoY, and cash and equivalents totaled $30.81M, with a net loss of $12M for the year.
The company did not provide a consolidated forecast for FY2026, citing ongoing strategic collaboration and out-licensing activities, but anticipated FY2026 operating expenses of approximately $16.2M, up 18% versus FY2025, with R&D spend expected to increase due to ongoing clinical trials. Development continues on MN-166 (ibudilast) for progressive multiple sclerosis, ALS, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and ARDS prevention, and on MN-001 (tipelukast) for NAFLD and hypertriglyceridemia. During 2025, the company recognized revenue under its Mayo Foundation agreement, entered into a standby equity purchase agreement with Yorkville and an equity distribution agreement with Lucid, and in January 2026 granted 980,000 stock options to executive officers.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $6.8M | $40M | $2.8M-$11M operating cash flow | report ↗ |
| 2023-FY | $1.0M | $5.3M | $51M | $2.1M-$7.4M operating cash flow | report ↗ |
| 2022-FY | — | $8.7M | $19M+ $40M short-term inv. | $3.5M-$13M operating cash flow | report ↗ |
| 2021-FY | $4.0M | $8.1M | $71M | $2.5M-$9.4M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 1 sale ($1.7M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-25 | 3D Investment Partners Pte. Ltd.; 3D Opportunity Master Fund · Formerly 10% Owner; Formerly 10% Owner | Open-market sale | 640,000 | $2.70 | $1.7M | Form 4 |
| 2026-06-23 | BEAVER CAROLYN · director | Award / grant (derivative) | 44,500 | — | — | Form 4 |
| 2026-06-23 | Lemerond Nicole · director | Award / grant (derivative) | 44,500 | — | — | Form 4 |
| 2026-06-23 | Nagao Hideki · director | Award / grant (derivative) | 44,500 | — | — | Form 4 |
| 2026-01-16 | IWAKI YUICHI · President and CEO | Award / grant (derivative) | 450,000 | — | — | Form 4 |
| 2026-01-16 | Matsuda Kazuko · Chief Medical Officer | Award / grant (derivative) | 350,000 | — | — | Form 4 |
| 2025-06-17 | BEAVER CAROLYN · director | Award / grant (derivative) | 20,000 | — | — | Form 4 |
| 2025-06-17 | Lemerond Nicole · director | Award / grant (derivative) | 20,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 30 reporting institutions held 5.4M shares ($7.4M, 11.0% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Essex Woodlands Management, Inc. | 1,105,941 | $1.5M |
| 2 | BlackRock, Inc. | 705,954 | $967K |
| 3 | CITIGROUP INC | 635,715 | $871K |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 611,039 | $837K |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 543,843 | $745K |
| 6 | VANGUARD FIDUCIARY TRUST CO | 280,621 | $384K |
| 7 | UBS Group AG | 222,200 | $304K |
| 8 | STATE STREET CORP | 193,698 | $265K |
| 9 | RENAISSANCE TECHNOLOGIES LLC | 189,900 | $260K |
| 10 | BARCLAYS PLC | 162,900 | $223K |
| 11 | NORTHERN TRUST CORP | 133,163 | $182K |
| 12 | JANE STREET GROUP, LLC | 87,085 | $119K |
| 13 | Bank of New York Mellon Corp | 78,277 | $107K |
| 14 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 71,506 | $98K |
| 15 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 56,031 | $77K |